Value-Based Care

This JMCP study compares pay-for-success and pay-for-failure models to identify the short- and long-term incentives for each that manufacturer and payer should when developing value-based contracts. More research is needed on the effect of different types of value-based contract schemes on cost and clinical outcome.

Although interest in value assessment frameworks is relatively widespread among payers, significant challenges to operationalizing them exist within the U.S. healthcare system. Those challenges--which include existing policies and a lack of standardized definitions--restrict the ability to make favorable contracts.

Although interest in value assessment frameworks is relatively widespread among payers, significant challenges to operationalizing them exist within the U.S. healthcare system. Those challenges--which include existing policies and a lack of standardized definitions--restrict the ability to make favorable contracts.

Genomic testing technology is rapidly evolving, but these test are costly and analytically complex. This article, published in JMCP, suggests a standardized method for the development and application of clinically relevant genomic testing.

Genomic testing technology is rapidly evolving, but these test are costly and analytically complex. This article, published in the JMCP, suggests a standardized method for the development and application of clinically relevant genomic testing.

AMCP supports the use of value frameworks as a resource for determining the value of pharmaceuticals and other health technologies when the Frameworks are based on sound methods using good scientific evidence and economic models.